| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| Other Sizes |
|
| ln Vitro |
In a cell line-dependent way, Dp44mT (compound C7) (0-80 μM, 48 h) triggers the lytic cycle; its induction ability in AGS-BX1 cells is higher than that in AGX cells [1]. In a time-dependent manner, the lytic cycle is induced by Dp44mT (10 μM, 0-72 h) [1]. Inducing the EBV lytic cycle, Dp44mT (1.25-2.5 μM, 24 h) works in concert with SAHA and Romidespin, two HDAC inhibitors [1]. Dp44mT (20 μM, 48 h) induces the ERK-autophage axis, which reactivates the EBV lytic cycle [2].
|
|---|---|
| Cell Assay |
Immunofluorescence[1]
Cell Types: AGS AGS-BX1 Tested Concentrations: 10 μM Incubation Duration: 24 h, 48 h, 72 h Experimental Results: Resulted the expression of IE proteins Zta, Rta, and early EBV lytic protein BMRF1 peaking at 24h post treatment. Immunofluorescence[1] Cell Types: AGS-BX1 Tested Concentrations: 1.25 μM, 2.5 μM Incubation Duration: 24 h Experimental Results: Synergistically induced the expression of the viral IE protein Zta could together with 2.5 μM of SAHA and 2.5 nM of Rmidepsin. Immunofluorescence[2] Cell Types: HA cells Tested Concentrations: 20 μM Incubation Duration: 24 h Experimental Results: A Dramatically lower expression of Zta was observed in cells treated with the iron-precomplexed C7 when compared to cells treated with C7 with 41% higher. Cell Proliferation Assay[1] Cell Types: AGS, AGS-BX1 Tested Concentrations: 0 μM, 1.25 μM, 2.5 μM, 5 μM, 10 μM, 20 μM, 40 μM, 80 μM Incubation Duration: 48 h Experimental Results: Displayed Dramatically higher toxicity to the EBV-positive cell line AGS-BX1 than the EBV-negative counterpart. |
| References |
[1]. Chung King Choi, et al. Identification of Novel Small Organic Compounds with Diverse Structures for the Induction of Epstein-Barr Virus (EBV) Lytic Cycle in EBV-Positive Epithelial Malignancies. PLoS One. 2015 Dec 30;10(12):e0145994.
[2]. Stephanie Pei Tung Yiu, et al. Intracellular Iron Chelation by a Novel Compound, C7, Reactivates Epstein–Barr Virus (EBV) Lytic Cycle via the ERK-Autophagy Axis in EBV-Positive Epithelial Cancers Cancers 2018 Dec; 10(12): 505. |
| Molecular Formula |
C14H12BRN3O
|
|---|---|
| Molecular Weight |
318.17
|
| CAS # |
394668-43-0
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Solubility (In Vitro) |
DMSO : ~12.5 mg/mL (~39.29 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 0.56 mg/mL (1.76 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 5.6 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 0.56 mg/mL (1.76 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 5.6 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 0.56 mg/mL (1.76 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1430 mL | 15.7149 mL | 31.4297 mL | |
| 5 mM | 0.6286 mL | 3.1430 mL | 6.2859 mL | |
| 10 mM | 0.3143 mL | 1.5715 mL | 3.1430 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
